Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How the cholestatic liver disease market is creating new opportunities for NTCP-targeting therapies
Assembly Biosciences is expanding ABI-6250 into PBC and PSC. Find out why NTCP-targeting therapies are gaining momentum in hepatology.
Is Lantheus (LNTH) the next big radiopharma target after Curium’s takeover move?
Curium’s $7B Lantheus move exposes radiopharma’s scarcity premium. See why oncology imaging assets are becoming M&A targets.
Mayne Pharma secures A$13.3m legal costs award from Cosette as MYX investors weigh takeover fallout
Mayne Pharma wins A$13.27m legal-costs award from Cosette as MYX investors weigh takeover fallout. Read more on the market impact.
Anupam Rasayan to acquire up to 48.2% stake in Bliss GVS Pharma as #ANURAS expands pharma value-chain bet
Anupam Rasayan is moving beyond chemistry into formulations. Can the Bliss GVS Pharma deal justify the market’s high expectations?
How the RNA therapeutics sector is shifting focus toward manufacturing scalability challenges
Explore why RNA therapeutics companies are increasingly prioritizing manufacturing scalability, stereochemical control, and industrial RNA production efficiency.
Why next-generation MDMA therapeutics are becoming the new battleground in psychedelic biotech
Why next-generation MDMA therapeutics are reshaping psychedelic biotech strategy, investor expectations, and commercialization competition.
ImmuPharma at 4p is a P140 licensing bet: What IMM retail investors should know
ImmuPharma targets a P140 licensing deal in 2026 with cash to H2 2028. Here is what IMM retail investors need to weigh before chasing the small-cap biotech.
Lilly (LLY) acquires Engage Biologics for up to $202m to advance non-viral DNA delivery platform
Eli Lilly (NYSE: LLY) acquires Engage Biologics for up to $202 million, adding the Tethosome non-viral DNA platform to its genetic medicines portfolio. Read more.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.
Avacta FY25 puts AVCT on a clock: ÂŁ16.9m cash, two Phase 1 reads, one shot
Avacta Group posts FY25 results with two clinical assets in trial, ÂŁ16.9m cash, and AVA6103 data due in H2 2026 as AVCT trades near 52-week high.